



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

22 February 2023  
EMA/68497/2023  
EMA/H/C/001127

## Public statement

---

# Temozolomide Hexal (temozolomide)

## Withdrawal of the marketing authorisation in the European Union

On 15 September 2022, the European Commission withdrew the marketing authorisation for Temozolomide Hexal (temozolomide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Hexal AG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Temozolomide Hexal was granted marketing authorisation in the EU on 15 March 2010 for treatment of:

- adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment,
- children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Temozolomide Hexal is a generic medicine of Temodal. There are other generic medicinal products of Temodal authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Temozolomide Hexal will be updated to indicate that the marketing authorisation is no longer valid.

